Journal: New England Journal of Medicine 2016

Author: Nevens et al. for the POISE Study Group*

Summary: Nevens et al. (Aug. 18 issue)1 highlight the efficacy and safety of obeticholic acid in patients with primary biliary cholangitis. The inclusion of a trial with a short follow-up of 1 year for a disease with an estimated duration of one to two decades without intervention certainly dilutes the information that is needed for the analysis of clinically relevant outcomes. Appropriate criteria that define the treatment duration and response with new regimens for primary biliary cholangitis are unknown

Read paper